The Center for Technology Licensing (CTL) is Cornell University's technology transfer office.
We manage technology for Cornell's Ithaca campus, Weill Cornell Medical Colleges, Cornell Tech, and Cornell AgriTech in Geneva.
Liquid cultures of A. tumefaciens strains, should have
antibiotics added at the Concentrations indicated for the stabs.
In particular, pCH30 and pCH32 are not stable in the absence
of selection (tetracycline).
To select for inserts in the sacB gene we plate out E. coli cells on LB + 40 mg/L kanamycin + 5% sucrose.
[For library preparation we use LB + 80 mg/L kanamycin, to reduce
a common contaminant in commercially available DH10B ElectroMAX
competent cells (BRL).]
The sacB gene also works in Agrobacterium. So Agrobacterium strains that contain the BIBAC vector without
insert will be sensitive to high levels of sucrose. Check your
co-cultivation medium; if it contains high levels of sucrose,
then the Agrobacterium cells will be killed. We substituted
glucose with no problems. This is not a problem for BIBAC + insert,
since the sacB gene has been inactivated.
You can use your standard plant transformation protocol. The
only modification that we made (mentioned in the PNAS paper)
was to increase the concentration of the Agrobacterium
cells/ml that was used to dip the tobacco leaf strips. This did
improve efficiency. We are currently testing this modification
for tomato transformation.
BIBAC technology and related materials are available for licensing. The “intellectual property” that is the basis of BIBAC technology is the “backbone” of the binary-BAC plasmid. The “backbone” plasmid (pCH20) does not contain any plant selectable markers. Cornell expects that (most) potential licensees will want to introduce proprietary markers. The BIBAC vector was designed with this in mind, and can be easily modified to specifications.
For non-profit organizations to request BIBAC materials for research purpose only, please contact the Center for Technology Licensing at Cornell University (CTL) at email@example.com under the subject of D1639 material request. A Material Transfer Agreement will be prepared according the request. Please be advised that due to the fact that the inventor of BIBAC is no longer at Cornell, a fee of $240 will be charged to reimburse the expense in maintaining the materials and in shipping and handling. For commercial entities to request BIBAC materials and license information, please contact Carolyn Theodore (firstname.lastname@example.org) at CTL.
Once you have permission from Syngenta to use MOG101 (this strain was formerly owned by MOGEN International), then all of the strains derived from MOG101 by Carol Hamilton will be available for your use.
MOG101 derived materials
Derivatives of MOG101 [C58 pMOG101]
UIA143: recA- deletion of C58